Evidence map›Paper›PMID 19014770›Full record

Trial reportThe Journal of allergy and clinical immunology2008

Effects of time, albuterol, and budesonide on the shape of the flow-volume loop in children with asthma.

Anand C Patel, Mark L Van Natta, James Tonascia, Robert A Wise, Robert C Strunk, Childhood Asthma Management Program Research Group

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The Journal of allergy and clinical immunology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 81% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Anand C PatelDivision of Allergy/Pulmonary Medicine, Department of Pediatrics, Washington University School of Medicine, and St Louis Children's Hospital, St Louis, Mo. Electronic address: patel_an@kids.wustl.edu.
Mark L Van NattaChildhood Asthma Management Program Coordinating Center, the Johns Hopkins Bloomberg School of Public Health, Baltimore, Md.
James TonasciaChildhood Asthma Management Program Coordinating Center, the Johns Hopkins Bloomberg School of Public Health, Baltimore, Md.
Robert A WiseDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, the Johns Hopkins University School of Medicine, Baltimore, Md.
Robert C StrunkDivision of Allergy/Pulmonary Medicine, Department of Pediatrics, Washington University School of Medicine, and St Louis Children's Hospital, St Louis, Mo.
Childhood Asthma Management Program Research Group
Johns Hopkins University · USSt. Louis Children's Hospital · USJohns Hopkins Medicine · US

Funding

ZOPOLRESTAT PHARMACOKINETICS IN DIABETICS WITH VARYING RENAL FUNCTIONM01RR000051 · NCRR · UNIVERSITY OF COLORADO DENVER · PI WALDERS, NATALIE · 1985 to 2008
$52.6M
ZUNI KIDNEY PROJECT STUDY I--POPULATION BASED SURVEY OF RENAL DISEASEM01RR000997 · NCRR · UNIVERSITY OF NEW MEXICO · PI LARSON, RICHARD S · 1985 to 2010
$30.0M
YOGA FOR THE MANAGEMENT OF HIV-METABOLIC SYNDROMESM01RR000036 · NCRR · WASHINGTON UNIVERSITY · PI POLONSKY, KENNETH S · 1985 to 2007
$25.4M
ZINC THERAPY FOR SCLERODERMA--PHASE I STUDYM01RR002719 · NCRR · JOHNS HOPKINS UNIVERSITY · PI EARLEY, CHRISTOPHER J · 1986 to 2007
$20.2M
PRINCIPLES IN PULMONARY RESEARCHT32HL007317 · NHLBI · WASHINGTON UNIVERSITY · PI Steven Brody, Michael J Holtzman · 1985 to 2026
$16.1M
CLINICAL CENTER FOR CAMPN01HR016049 · HR · BRIGHAM AND WOMEN'S HOSPITAL · PI WEISS, SCOTT T · 1991 to 2000
$1.0M
CLINICAL COORDINATING CENTER FOR CAMPN01HR016044 · HR · JOHNS HOPKINS UNIVERSITY · PI TONASCIA, JAMES A · 1991 to 2006
$729k
Role of Calcium-Activated Chloride Channels in Airway Disease PhenotypesK08HL083095 · NHLBI · WASHINGTON UNIVERSITY · PI PATEL, ANAND CHAMPAK · 2007 to 2011
$600k
CLINICAL CENTER FOR CAMPN01HR016047 · HR · HOSPITAL FOR SICK CHLDRN (TORONTO) · PI MACLUSKY, IAN B · 1991 to 2000
$0k
CLINICAL CENTER FOR CAMPN01HR016048 · HR · NATIONAL JEWISH HEALTH · PI SZEFLER, STANLEY J · 1991 to 2000
$0k
CLINICAL CENTER FOR CAMPN01HR016046 · HR · UNIVERSITY OF NEW MEXICO · PI KELLY, H W · 1991 to 2000
$0k
CLINICAL CENTER FOR CAMPN01HR016050 · HR · ASTHMA, INC. · PI SHAPIRO, GAIL G · 1991 to 2000
$0k
NCRR NIH HHS M01 RR000036NCRR NIH HHS M01 RR000051NCRR NIH HHS M01 RR00051NCRR NIH HHS M01 RR000997NCRR NIH HHS M01 RR002719NCRR NIH HHS M01 RR0099718-24NCRR NIH HHS M01 RR02719-14NCRR NIH HHS RR00036NHLBI NIH HHS K08 HL083095NHLBI NIH HHS N01 HR016044NHLBI NIH HHS N01-HR-16044NHLBI NIH HHS N01-HR-16045NHLBI NIH HHS N01-HR-16046NHLBI NIH HHS N01-HR-16047NHLBI NIH HHS N01-HR-16048NHLBI NIH HHS N01-HR-16049NHLBI NIH HHS N01-HR-16050NHLBI NIH HHS N01-HR-16051NHLBI NIH HHS N01-HR-16052NHLBI NIH HHS T32 HL007317
6 · The paper itself

Abstract

backgroundAssessment of asthma through spirometric analysis in children is challenging because of often normal FEV(1) values.

objectiveWe used Mead's slope ratio (SR; (dV /dV)/(V /V)) to analyze the shape of the flow-volume loop.

methodsWe analyzed the effects of time, albuterol, and budesonide on FEV(1), FEV(1)/forced vital capacity (FVC) ratio, forced expiratory flow from 25% to 75% of expired volume, and Mead's SR both early (between 75% and 50% of FVC, SR61) and late (between 75% and 50% of FVC, SR35) in exhalation in the Childhood Asthma Management Program cohort at baseline, 4 months, and the end of the study in participants who received either inhaled placebo or budesonide twice daily.

resultsIn the placebo group both SR61 and SR35 improved over time. Bronchodilator consistently improved both SR61 and SR35, without change in degree of improvement over time. Similarly, in the budesonide group time and bronchodilator each independently improved both SR61 and SR35. At 4 months and the end of the study, patients receiving budesonide had significant improvements in SR61 relative to patients receiving placebo, which was independent of bronchodilator effect. Budesonide and placebo were not different with respect to prebronchodilator or postbronchodilator SR35.

conclusionBudesonide-treated patients have less concave flow-volume loops when compared with placebo-treated patients. Time and bronchodilator also make the flow-volume loop less concave. Furthermore, it appears that there are discrete bronchodilator- and corticosteroid-responsive components of airflow obstruction in pediatric asthma.

Indexed as

AlbuterolAsthmaBronchodilator AgentsBudesonideChildChild, PreschoolCohort StudiesFemaleForced Expiratory Flow RatesHumansMaleTime FactorsVital CapacityAlbuterolBronchodilator AgentsBudesonide

Identifiers

PMID19014770
PMCPMC2881659
OpenAlexW2118223908

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.